Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.219
Neutral
RSI(14)
50.844
Neutral
STOCH(KDJ)(9,3,3)
35.715
Sell
ATR(14)
1.377
High Vlolatility
CCI(14)
-38.252
Neutral
Williams %R
66.816
Sell
TRIX(12,20)
0.276
Sell
StochRSI(14)
26.299
Buy
IDEAYA Biosciences Inc
IDYA24.930USD
+0.220+0.89%
Close 09/11, 16:00（ET）Quotes delayed by 15 min
2.18BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Currency: USD Updated：2025-09-10Key Insights
The company's fundamentals are relatively weak. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
18
analysts
Buy
Current Rating
45.000
Target Price
+82.11%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates are darovasertib (IDE196), IDE397, IDE161 and GSK101 (Pol Theta Helicase). IDE196, a small molecule protein kinase C (PKC), inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397, is its small molecule methionine adenosyltransferase 2a (MAT2A), inhibitor. IDE161, is its small molecule poly (ADP-ribose) glycohydrolase (PARG), inhibitor. IDE196 is its clinical-stage PKC inhibitor that the Company is evaluating as a synthetic lethal combination therapy. IDE397, a MAT2A inhibitor for patients with solid tumors having MTAP deletions. IDE161 is its clinical-stage, potent and selective small molecule inhibitor of PARG for patients having tumors with defined biomarkers based on genetic mutations and/or molecular signatures.
Growing
The company is in a growing phase, with the latest annual income totaling USD 7.00M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 367.95.
Undervalued
The company’s latest PE is -6.42, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 101.70M shares, decreasing 5.85% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 5.03M shares of this stock.
Financial Health
Currency: USD Updated：2025-09-10The company's current financial score is 5.19, which is lower than the Biotechnology & Medical Research industry's average of 6.80. Its financial status is weak, and its operating efficiency is low.
Score
Financials
2.04
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Quality of Earnings
7.26
Operational Efficiency
2.67
Growth Potential
6.95
Shareholder Returns
7.03
Company Valuation
Currency: USD Updated：2025-09-10The company’s current valuation score is 1.20, which is lower than the Biotechnology & Medical Research industry's average of 1.64. Its current P/E ratio is -6.50, which is -19.45% below the recent high of -5.23 and 7.61% above the recent low of -6.00.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 77/509
No Data
Earnings Forecast
Currency: USD Updated：2025-09-10The company’s current earnings forecast score is 8.50, which is higher than the Biotechnology & Medical Research industry's average of 7.96. The average price target for IDEAYA Biosciences Inc is 45.00, with a high of 64.00 and a low of 25.00.
Score
Support & Resistance
No Data
Analyst Rating
Based on
18
analysts
Buy
Current Rating
45.000
Target Price
+82.11%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
IDEAYA Biosciences Inc
IDYA
18
CRISPR Therapeutics AG
CRSP
30
Intellia Therapeutics Inc
NTLA
26
Exact Sciences Corp
EXAS
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
No Data
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated：2025-09-10The company’s current price momentum score is 9.22, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 26.52 and the support level at 22.79, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
25.166
Sell
MA10
25.155
Sell
MA20
24.855
Buy
MA50
23.765
Buy
MA100
21.882
Buy
MA200
21.969
Buy
Institutional Confidence
Currency: USD Updated：2025-09-10The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 6.02. The latest institutional shareholding proportion is 116.06%, representing a quarter-over-quarter increase of 3.92%. The largest institutional shareholder is Steven Cohen, holding a total of 5.03M shares, representing 5.74% of shares outstanding, with 1.00% increase in holdings.
Score
Institutional Shareholding
No Data
Shareholder Activity
Name
Shares Held
Chg %
Fidelity Management & Research Company LLC
BlackRock Institutional Trust Company, N.A.
Capital Research Global Investors
Janus Henderson Investors
Federated Hermes Global Investment Management Corp.
Deerfield Management Company, L.P.
State Street Global Advisors (US)
Logos Global Management LP
1
2
Risk Assessment
Currency: USD Updated：2025-09-10The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Biotechnology & Medical Research mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 3.15, which is lower than the Biotechnology & Medical Research industry's average of 3.51. The company's beta value is 0.12. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.13
VaR
+5.26%
240-Day Maximum Drawdown
+57.01%
240-Day Volatility
+59.71%
Return
Best Daily Return
60 days
+7.31%
120 days
+10.70%
5 years
+35.70%
Worst Daily Return
60 days
-13.88%
120 days
-13.88%
5 years
-34.82%
Sharpe Ratio
60 days
+1.22
120 days
+1.20
5 years
+0.53
Risk Assessment
Maximum Drawdown
240 days
+57.01%
3 years
+69.23%
5 years
+69.42%
Return-to-Drawdown Ratio
240 days
-0.47
3 years
+0.26
5 years
+0.25
Skewness
240 days
-0.35
3 years
+1.74
5 years
+0.33
Volatility
Realised Volatility
240 days
+59.71%
5 years
+66.27%
Standardised True Range
240 days
+4.89%
5 years
+5.01%
Downside Risk-Adjusted Return
120 days
+158.17%
240 days
+158.17%
Maximum Daily Upside Volatility
60 days
+35.05%
Maximum Daily Downside Volatility
60 days
+39.35%
Liquidity
Average Turnover Rate
60 days
+1.12%
120 days
+1.38%
5 years
--
Turnover Deviation
20 days
-21.59%
60 days
-10.87%
120 days
+9.98%
Peer Comparison
Currency: USD Updated：2025-09-10IDEAYA Biosciences Inc
IDYA
5.90 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Insmed Inc
INSM
7.30 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stoke Therapeutics Inc
STOK
7.21 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
7.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ionis Pharmaceuticals Inc
IONS
7.02 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Travere Therapeutics Inc
TVTX
7.01 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.
